ABSTRACT KEYWORDS: The prevalence of hypertension varies from percentages in all

Size: px
Start display at page:

Download "ABSTRACT KEYWORDS: The prevalence of hypertension varies from percentages in all"

Transcription

1 85 P a g e International Standard Serial Number (ISSN): International Journal of Universal Pharmacy and Bio Sciences 6(6): November-December 2017 INTERNATIONAL JOURNAL OF UNIVERSAL PHARMACY AND BIO SCIENCES IMPACT FACTOR 4.018*** ICV 6.16*** Pharmaceutical Sciences RESEARCH ARTICLE!!! THE EVALUATION OF EFFECTIVENESS OF ANTIHYPERTENSIVE AGENTS AS MONOTHERAPY OR COMBINATION THERAPY IN A TERTIARY CARE HOSPITAL Basil Sunny 1 *, Sophiya T Varghese 1, Hemalatha S 2, Sivakumar T 3 * 1 Pharm.D (Doctor of Pharmacy), Nandha college of Pharmacy. 2 Lecturer, Nandha college of Pharmacy. 3 Principal, Nandha college of Pharmacy. KEYWORDS: Hypertension, Monotherapy, JNC-8, Antihypertensive, Combination therapy. For Correspondence: Basil Sunny* Address: Nandha college of Pharmacy, Erode, Tamilnadu ABSTRACT The prevalence of hypertension varies from percentages in all states of India according to the ICMR survey. The rates are higher in old and obese patients. Hypertension doubles the risk of cardiovascular diseases, renal diseases, stroke, and retinal diseases. Our study was conducted in a tertiary care hospital and patients with systemic hypertension above the age of 18 were included in the study. This study was carried out in order to find out the efficacy of various antihypertensive therapeutic classes. Finally therapeutic goals were defined as per JNC 8. It was seen that fixed drug combination showed highest BP control than monotherapy and free equivalent combinations.

2 86 P a g e International Standard Serial Number (ISSN): INTRODUCTION: Hypertension can be defined as persistent increase in blood pressure to an extent that places a patient at elevated risk for target organ damage. About 75 lakhs(13-15%)and around 9 crores disability adjusted life years worldwide(daly) contributed by high BP in 2001.Hypertension doubles the risk of cardiovascular diseases like coronary vascular events, peripheral vascular disease, End stage renal disease, stroke, retinal disease(hypertensive retinopathy). According to Framingham study it has been shown that hypertensive patient have four fold increase in cardiovascular events and 6 fold increase in congestive heart failure in comparison with normotensive individuals. [1-3] Hypertension is like an iceberg disease since large segments of hypertensive population are unaware/inadequately treated/ untreated. In India as per ICMR survey ( ) prevalence of hypertension was varying from 17-21% in all the states. Prevalence of hypertension is higher in old and obese patients. Other risk factors are high sodium chloride intake, low calcium and potassium intake, alcohol consumption, psychosocial stress and low level of physical activity. [1,4] As per JNC 8 the pharmacologic treatment must be initiated when For patients < 60yrs of age, start treatment if BP is 140/90 mmhg For patients with diabetes, start treatment if BP is 140/90 mmhg For patients with CKD, start treatment if BP is 140/90 mmhg For patients 60yrs of age, start treatment if BP is 150/90 mmhg For patients < 80yrs of age, start treatment if BP is 140/90 mmhg For patients > 80yrs of age, start treatment if BP is 150/90 mmhg The risk of stroke could be reduced by lowering systolic BP by mmhg and diastolic BP by 5-6 mmhg and by 12-16% for CHF within 5 years of treatment initiation. By controlling hypertension we could minimise the rate of progression of hypertension allied kidney disease. Based of hypertension severity, age and other cardiovascular risks, comorbidities, side effects and frequency of dosing, individualization of the treatment must be done i.e. whether to prescribe combination treatment or individual drug. [5-8]

3 87 P a g e International Standard Serial Number (ISSN): MATERIAL AND METHODS: Data source: The study was conducted in a tertiary care hospital. The data were collected from the inpatient records; which include patient demographics, height, weight, diagnosis, comorbidities, laboratory data, medical and medication history, medication dosing frequency, mean BP, reduction in BP and JNC goal attainment. Cleaning: Inclusion criteria: Patients with systemic hypertension above the age of 18 were included in the study. Exclusion criteria: Those patients with recent attack of ischaemic stroke, MI were excluded from the study. Finally therapeutic goals were defined as per JNC8.For patients without any comorbidity (DM and CKD)BP control is defined as mean systolic BP <130 mmhg and mean diastolic BP < 80 mmhg and for patients with comorbidities (DM & CKD) BP control is defined as mean systolic BP <14O mmhg and mean diastolic BP < 90 mmhg respectively. Antihypertensive agents were classified into the following therapeutic classes: ACE inhibitors, ARB Blockers, Beta blockers, Calcium channel blockers, thiazides and thiazide like diuretics.all other antihypertensive therapeutic classes were excluded due to insufficient number for adequate analysis.

4 88 P a g e International Standard Serial Number (ISSN): RESULTS: 1. POPULATION CHARACTERSTICS DEMOGROGRAPHICS MALE 118 FEMALE 102 AGE < >80 9 COMORBIDITIES DM 68 CKD 10 TB 41 THYROID 35 CARDIAC JNC GOAL ATTAINMENT ACCORDING TO AGE AGE GOAL ATTAINED NOT ATTAINED < >80 8 2

5 89 P a g e International Standard Serial Number (ISSN): JNC GOAL ATTAINMENT IN PATIENTS WITH COMORBIDITIES COMORBIDITIES ATTAINED NOT ATTAINED DIABETIC CKD 0 10 OTHERS NO COMORBIDITIES MEAN BLOOD PRESSURE MONOTHERAPY CCB B- BLOCKER ACE INHIBITORS Mean systolic BP (mmhg) Mean diastolic BP (mmhg) Goal attainment (%) FDC CCB + DIURETIC ARB + DIURETIC Mean systolic BP (mmhg) Mean diastolic BP (mmhg) Goal attainment (%) FEC CCB + DIURETIC ACE + CCB ARB + DIURETIC Mean systolic BP (mmhg) Mean diastolic BP (mmhg) Goal attainment (%) V: GOAL ATTAINMENT BASED ON THERAPEUTIC CLASS THERAPEUTIC CLASS FEC FDC CCB + DIURETIC ARB + DIURETIC

6 90 P a g e International Standard Serial Number (ISSN): MONOTHERAPY FDC FEC GOAL ATTAINED DISCUSSION: The population individualities for all the 220 patients who were on antihypertensive therapy are shown in Table 1. Among them % are female patients and 53.63% are male patients. There were more geriatric patients and % of the patients had either diabetes, TB, CKD or other comorbidities which require lower JNC blood pressure goals. This study found that patients receiving antihypertensive therapy were on 1 of the 5 antihypertensive therapeutic classes as monotherapy and showed remarkably similar average reductions in blood pressure for FDC. These results are consistent with those found in an observational study carried out by Michael R. Bronsert et al., in 2013 to compare the effectiveness of different antihypertensive therapeutic classes stated that monotherapy also had similar reductions in BP as FDC. [1] In spite of similar BP reduction among different therapeutic classes, B- blockers showed higher rates of JNC8 goal attainment in patients initiated with monotherapy followed by ACE inhibitors.

7 91 P a g e International Standard Serial Number (ISSN): It was observed that patients who were on FDC antihypertensive treatment had substantially greater reductions in BP and higher JNC goal attainment rates than patients on monotherapy(table 4).Among FDC two combinations were selected, that is CCB + Diuretic and ARB + Diuretic and it showed 91.8% of goal attainment for CCB + Diuretic combination and 87.6% for ARB + Diuretic. A cross-sectional survey conducted by Roas S et al., on Antihypertensive combination in primary care settings indicated that patients initiated on FDC obtain better control of BP than patients initiated on monotherapy alone. [9] The patients who were on FEC tend to have lower goal attainment as compared to monotherapy and FDC. Among FEC three combinations were included in the study, which comprise of CCB + Diuretic, ACE inhibitors + CCB and ARB + Diuretic. Among them ACE inhibitors + CCB showed higher effectiveness (85.2%) as compared with CCB + Diuretic (72.1%) and ARB + Diuretic (64.6%). On analysing the JNC goal attainment based on therapeutic class for both FEC and FDC,it was found that for CCB + Diuretic 72.1% of patients have controlled BP in FEC and 91.8 % for FDC. In case of ARB + Diuretic 64.6% of patients had controlled BP in FEC and 87.6% in FDC. As per JNC8 guidelines for hypertension, patients with diabetes and CKD only require 140/90 for their goal attainment whereas for patients without comorbidities require 130/80 for the same. From this study it was found that only 46% of diabetic patients attainted their therapeutic goal whereas for CKD patients none attained their therapeutic goal. For patients without comorbidities 18% shown goal attainment. CONCLUSION: Antihypertensives continue to be one of the highly consumed drugs all over the world. Coming to the effectiveness of antihypertensive therapy JNC has launched certain guidelines for BP reduction. This study was carried out in order to find out the efficacy of various antihypertensive therapeutic classes. It was seen that FDC showed highest BP control followed by monotherapy and FEC.

8 92 P a g e International Standard Serial Number (ISSN): REFERENCES 1. Michael R. Bronsert, (2013), Comparative Effectiveness of Antihypertensive Therapeutic Classes and Treatment Strategies in the Initiation of Therapy in Primary Care Patients: A Distributed Ambulatory Research in Therapeutics Network (DARTNet) Study.J Am Board Fam Med. 26(5): doi: /jabfm CoreyFoster.,Neville F Mistry (2011).The washington manual of medicinal therapeutics.lippincott wilams and wilkins Bakris GL, Weir MR(2003). Study of Hypertension and the Efficacy of Lotrel in Diabetes (SHIELD) Investigators. Achieving goal blood pressure in patients with type 2 diabetes: Conventional versus fixed-dose combination approaches. J ClinHypertens (Greenwich);5: BaserO,AndrewsLM,WangL,XieL(2011).Comparison of real-world adherence, healthcare resource utilization and costs for newly initiated valsartan/amlodipine singepill combination versus angiotensin receptor blocker/calcium channel blocker freecombination therapy. J Med Econ;14: Journals afp Vol. 90/No. 7(October 1, 2014) 6. Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH, Weiss NS(2003). Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA;289: Gradman AH, Basile JN, Carter BL, Bakris GL(2010). Combination therapy in hypertension. J Am Soc Hypertens;4: Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ(2009). Combination therapy versus monotherapy in reducingbloodpressure:meta-analysison11,000participants from 42 trials. Am J Med;122: Susanne Roas(2014). Antihypertensive combination therapy in primary care offices: results of a cross-sectional survey in Switzerland.International Journal ofgeneral Medicine;7: doi: /IJGM.S74023.

JNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults

JNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults JNC 8 2014 Evidence-Based Guidelines for the Management of High Blood Pressure in Adults Table of Contents Why Do We Treat Hypertension? Blood Pressure Treatment Goals Initial Therapy Strength of Recommendation

More information

Original article: A Study of prescription pattern of antihypertensive drugs in a tertiary Care teaching hospital

Original article: A Study of prescription pattern of antihypertensive drugs in a tertiary Care teaching hospital Original article: A Study of prescription pattern of antihypertensive drugs in a tertiary Care teaching hospital Pyarelal Associate Professor, Department of Pharmacology, Mediciti Institute of Medical

More information

Clinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8. Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital

Clinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8. Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital Clinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8 Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital Objectives Review the Eighth Joint National Committee (JNC

More information

Long-Term Care Updates

Long-Term Care Updates Long-Term Care Updates August 2015 By Darren Hein, PharmD Hypertension is a clinical condition in which the force of blood pushing on the arteries is higher than normal. This increases the risk for heart

More information

Int. J. Pharm. Sci. Rev. Res., 36(1), January February 2016; Article No. 06, Pages: JNC 8 versus JNC 7 Understanding the Evidences

Int. J. Pharm. Sci. Rev. Res., 36(1), January February 2016; Article No. 06, Pages: JNC 8 versus JNC 7 Understanding the Evidences Research Article JNC 8 versus JNC 7 Understanding the Evidences Anns Clara Joseph, Karthik MS, Sivasakthi R, Venkatanarayanan R, Sam Johnson Udaya Chander J* RVS College of Pharmaceutical Sciences, Coimbatore,

More information

First line treatment of primary hypertension

First line treatment of primary hypertension First line treatment of primary hypertension Dr. Vijaya Musini Assistant Professor, Dept. Anesthesiology, Pharmacology and Therapeutics Manager, Drug Assessment Working Group Therapeutics Initiative Editor,

More information

DISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose.

DISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose. JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES Tiffany Dickey, PharmD Assistant Professor, UAMS COP Clinical Pharmacy Specialist, Mercy Hospital Northwest AR DISCLOSURE I

More information

What s In the New Hypertension Guidelines?

What s In the New Hypertension Guidelines? American College of Physicians Ohio/Air Force Chapters 2018 Scientific Meeting Columbus, OH October 5, 2018 What s In the New Hypertension Guidelines? Max C. Reif, MD, FACP Objectives: At the end of the

More information

Diabetes and Hypertension

Diabetes and Hypertension Diabetes and Hypertension M.Nakhjvani,M.D Tehran University of Medical Sciences 20-8-96 Hypertension Common DM comorbidity Prevalence depends on diabetes type, age, BMI, ethnicity Major risk factor for

More information

Prevention of Heart Failure: What s New with Hypertension

Prevention of Heart Failure: What s New with Hypertension Prevention of Heart Failure: What s New with Hypertension Ali AlMasood Prince Sultan Cardiac Center Riyadh 3ed Saudi Heart Failure conference, Jeddah, 13 December 2014 Background 20-30% of Saudi adults

More information

International Journal of Advancements in Research & Technology, Volume 2, Issue 6, June-2013 ISSN

International Journal of Advancements in Research & Technology, Volume 2, Issue 6, June-2013 ISSN ISSN 2278-7763 295 Study of Prescriptive Patterns of Antihypertensive Drugs in South India Popuri Rupa Sindhu, Malladi Srinivas Reddy St. Peters Institute of Pharmaceutical Sciences, Hanamkonda, Warangal-506001,

More information

Antihypertensive Combinations

Antihypertensive Combinations This Professional Resource gives subscribers additional insight related to the Recommendations published in PHARMACIST S LETTER / PRESCRIBER S LETTER October 2016 ~ Resource #321047 Antihypertensive Combinations

More information

Prescription Pattern of Anti-Hypertensive Drugs in Adherence to JNC- 7 Guidelines

Prescription Pattern of Anti-Hypertensive Drugs in Adherence to JNC- 7 Guidelines American Journal of Pharmacology and Toxicology Original Research Paper Prescription Pattern of Anti-Hypertensive Drugs in Adherence to JNC- 7 Guidelines 1 Krishna Murti, 1 M. Arif Khan, 1 Akalanka Dey,

More information

EFFICACY & SAFETY OF ORAL TRIPLE DRUG COMBINATION OF TELMISARTAN, AMLODIPINE AND HYDROCHLOROTHIAZIDE IN THE MANAGEMENT OF NON-DIABETIC HYPERTENSION

EFFICACY & SAFETY OF ORAL TRIPLE DRUG COMBINATION OF TELMISARTAN, AMLODIPINE AND HYDROCHLOROTHIAZIDE IN THE MANAGEMENT OF NON-DIABETIC HYPERTENSION EFFICACY & SAFETY OF ORAL TRIPLE DRUG COMBINATION OF TELMISARTAN, AMLODIPINE AND HYDROCHLOROTHIAZIDE IN THE MANAGEMENT OF NON-DIABETIC HYPERTENSION Khemchandani D. 1 and * Arif A. Faruqui 2 1 Bairagarh,

More information

Todd S. Perlstein, MD FIFTH ANNUAL SYMPOSIUM

Todd S. Perlstein, MD FIFTH ANNUAL SYMPOSIUM Todd S. Perlstein, MD FIFTH ANNUAL SYMPOSIUM Faculty Disclosure I have no financial interest to disclose No off-label use of medications will be discussed FIFTH ANNUAL SYMPOSIUM Recognize changes between

More information

New Hypertension Guideline Recommendations for Adults July 7, :45-9:30am

New Hypertension Guideline Recommendations for Adults July 7, :45-9:30am Advances in Cardiovascular Disease 30 th Annual Convention and Reunion UERM-CMAA, Inc. Annual Convention and Scientific Meeting July 5-8, 2018 New Hypertension Guideline Recommendations for Adults July

More information

Hypertension Management: A Moving Target

Hypertension Management: A Moving Target 9:45 :30am Hypertension Management: A Moving Target SPEAKER Karol Watson, MD, PhD, FACC Presenter Disclosure Information The following relationships exist related to this presentation: Karol E. Watson,

More information

HYPERTENSION GUIDELINES WHERE ARE WE IN 2014

HYPERTENSION GUIDELINES WHERE ARE WE IN 2014 HYPERTENSION GUIDELINES WHERE ARE WE IN 2014 Donald J. DiPette MD FACP Special Assistant to the Provost for Health Affairs Distinguished Health Sciences Professor University of South Carolina University

More information

Hypertension and Cardiovascular Disease

Hypertension and Cardiovascular Disease Hypertension and Cardiovascular Disease Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic,

More information

Diversity and HTN: Approaches to optimal BP control in AfricanAmericans

Diversity and HTN: Approaches to optimal BP control in AfricanAmericans Diversity and HTN: Approaches to optimal BP control in AfricanAmericans Quinn Capers, IV, MD, FACC, FSCAI Assistant Professor of Medicine Associate Dean for Admissions Do Racial Differences Really Exist

More information

5.2 Key priorities for implementation

5.2 Key priorities for implementation 5.2 Key priorities for implementation From the full set of recommendations, the GDG selected ten key priorities for implementation. The criteria used for selecting these recommendations are listed in detail

More information

New Hypertension Guidelines: Why the change? Neil Brummond, M.D. Avera Medical Group Internal Medicine Sioux Falls, SD

New Hypertension Guidelines: Why the change? Neil Brummond, M.D. Avera Medical Group Internal Medicine Sioux Falls, SD New Hypertension Guidelines: Why the change? Neil Brummond, M.D. Avera Medical Group Internal Medicine Sioux Falls, SD None Disclosures Objectives Understand trend in blood pressure clinical practice guidelines

More information

47 Hypertension in Elderly

47 Hypertension in Elderly 47 Hypertension in Elderly YOU DO NOT HEAL OLD AGE; YOU PROTECT IT; YOU PROMOTE IT; YOU EXTEND IT Sir James Sterling Ross Abstract: The prevalence of hypertension rises with age and the complications secondary

More information

Pre-ALLHAT Drug Use. Diuretics. ß-Blockers. ACE Inhibitors. CCBs. Year. % of Treated Patients on Medication. CCBs. Beta Blockers.

Pre-ALLHAT Drug Use. Diuretics. ß-Blockers. ACE Inhibitors. CCBs. Year. % of Treated Patients on Medication. CCBs. Beta Blockers. Pre- Drug Use % of Treated Patients on Medication 60 50 40 30 20 10 0 1978 Diuretics ß-Blockers ACE Inhibitors Year CCBs CCBs Beta Blockers Diuretics ACE Inhibitors 1980 1982 1984 1986 1988 1990 1992 IMS

More information

Hypertension Management Controversies in the Elderly Patient

Hypertension Management Controversies in the Elderly Patient Hypertension Management Controversies in the Elderly Patient Juan Bowen, MD Geriatric Update for the Primary Care Provider November 17, 2016 2016 MFMER slide-1 Disclosure No financial relationships No

More information

Hypertension Update 2016 AREEF ISHANI, MD MS CHIEF OF MEDICINE MINNEAPOLIS VA MEDICAL CENTER PROFESSOR OF MEDICINE UNIVERSITY OF MINNESOTA

Hypertension Update 2016 AREEF ISHANI, MD MS CHIEF OF MEDICINE MINNEAPOLIS VA MEDICAL CENTER PROFESSOR OF MEDICINE UNIVERSITY OF MINNESOTA Hypertension Update 2016 AREEF ISHANI, MD MS CHIEF OF MEDICINE MINNEAPOLIS VA MEDICAL CENTER PROFESSOR OF MEDICINE UNIVERSITY OF MINNESOTA Case 1 What should be your BP goal for an elderly (> 75 yrs of

More information

Which antihypertensives are more effective in reducing diastolic hypertension versus systolic hypertension? May 24, 2017

Which antihypertensives are more effective in reducing diastolic hypertension versus systolic hypertension? May 24, 2017 Which antihypertensives are more effective in reducing diastolic hypertension versus systolic hypertension? May 24, 2017 The most important reason for treating hypertension in primary care is to prevent

More information

Egyptian Hypertension Guidelines

Egyptian Hypertension Guidelines Egyptian Hypertension Guidelines 2014 Egyptian Hypertension Guidelines Dalia R. ElRemissy, MD Lecturer of Cardiovascular Medicine Cairo University Why Egyptian Guidelines? Guidelines developed for rich

More information

Objectives. Describe results and implications of recent landmark hypertension trials

Objectives. Describe results and implications of recent landmark hypertension trials Hypertension Update Daniel Schwartz, MD Assistant Professor of Medicine Associate Medical Director of Heart Transplantation Temple University School of Medicine Disclosures I currently have no relationships

More information

Hypertension Update Clinical Controversies Regarding Age and Race

Hypertension Update Clinical Controversies Regarding Age and Race Hypertension Update Clinical Controversies Regarding Age and Race Allison Helmer, PharmD, BCACP Assistant Clinical Professor Auburn University Harrison School of Pharmacy July 22, 2017 DISCLOSURE/CONFLICT

More information

DISCLOSURES OUTLINE OUTLINE 9/29/2014 ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE

DISCLOSURES OUTLINE OUTLINE 9/29/2014 ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE DISCLOSURES Editor-in-Chief- Nephrology- UpToDate- (Wolters Klewer) Richard J. Glassock, MD, MACP Geffen School of Medicine at UCLA 1 st Annual Internal

More information

4/4/17 HYPERTENSION TARGETS: WHAT DO WE DO NOW? SET THE STAGE BP IN CLINICAL TRIALS?

4/4/17 HYPERTENSION TARGETS: WHAT DO WE DO NOW? SET THE STAGE BP IN CLINICAL TRIALS? HYPERTENSION TARGETS: WHAT DO WE DO NOW? MICHAEL LEFEVRE, MD, MSPH PROFESSOR AND VICE CHAIR DEPARTMENT OF FAMILY AND COMMUNITY MEDICINE UNIVERSITY OF MISSOURI 4/4/17 DISCLOSURE: MEMBER OF THE JNC 8 PANEL

More information

TIP. Documentation and coding guide. Disease definitions* Prevalence and statistics associated with HTN**

TIP. Documentation and coding guide. Disease definitions* Prevalence and statistics associated with HTN** Documentation and coding guide Disease definitions* HTN is diagnosed when the average of two or more (systolic of diastolic) blood pressure readings are found to be elevated on two or more office visits

More information

Hypertension and obesity. Dr Wilson Sugut Moi teaching and referral hospital

Hypertension and obesity. Dr Wilson Sugut Moi teaching and referral hospital Hypertension and obesity Dr Wilson Sugut Moi teaching and referral hospital No conflict of interests to declare Obesity Definition: excessive weight that may impair health BMI Categories Underweight BMI

More information

HYPERTENSION: ARE WE GOING TOO LOW?

HYPERTENSION: ARE WE GOING TOO LOW? HYPERTENSION: ARE WE GOING TOO LOW? George L. Bakris, M.D.,F.A.S.N.,F.A.S.H., F.A.H.A. Professor of Medicine Director, ASH Comprehensive Hypertension Center University of Chicago Medicine Chicago, IL USA

More information

DEPARTMENT OF GENERAL MEDICINE WELCOMES

DEPARTMENT OF GENERAL MEDICINE WELCOMES DEPARTMENT OF GENERAL MEDICINE WELCOMES 1 Dr.Mohamed Omar Shariff, 2 nd Year Post Graduate, Department of General Medicine. DR.B.R.Ambedkar Medical College & Hospital. 2 INTRODUCTION Leading cause of global

More information

Combination Therapy for Hypertension

Combination Therapy for Hypertension Combination Therapy for Hypertension Se-Joong Rim, MD Cardiology Division, Yonsei University College of Medicine, Seoul, Korea Goals of Therapy Reduce CVD and renal morbidity and mortality. Treat to BP

More information

Target Blood Pressure Attainment in Diabetic Hypertensive Patients: Need for more Diuretics? Waleed M. Sweileh, PhD

Target Blood Pressure Attainment in Diabetic Hypertensive Patients: Need for more Diuretics? Waleed M. Sweileh, PhD Target Blood Pressure Attainment in Diabetic Hypertensive Patients: Need for more Diuretics? Waleed M. Sweileh, PhD Associate Professor, Clinical Pharmacology Corresponding author Waleed M. Sweileh, PhD

More information

VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005

VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005 VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005 1 Any adult in the health care system 2 Obtain blood pressure (BP) (Reliable,

More information

Hypertension JNC 8 (2014)

Hypertension JNC 8 (2014) Hypertension JNC 8 (2014) Renewed: February 2018 Updated: February 2015 Comparison of Seventh Joint National Committee (JNC 7) vs. Eighth Joint National Committee (JNC 8) Hypertension Guidelines Methodology

More information

ALLHAT. Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic

ALLHAT. Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic 1 U.S. Department of Health and Human Services National Institutes of Health Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker

More information

Update on Current Trends in Hypertension Management

Update on Current Trends in Hypertension Management Friday General Session Update on Current Trends in Hypertension Management Shawna Nesbitt, MD Associate Dean, Minority Student Affairs Associate Professor, Department of Internal Medicine Office of Student

More information

Management of Hypertension in special groups. DR-Mohammed Salah Assistant Lecturer of Cardiology Mansoura University

Management of Hypertension in special groups. DR-Mohammed Salah Assistant Lecturer of Cardiology Mansoura University Management of Hypertension in special groups BY DR-Mohammed Salah Assistant Lecturer of Cardiology Mansoura University AGENDA SPECIAL GROUPS SPECIFIC DRUDS FOR SPECIAL GROUPS TARGET BP FOR SPECIAL GROUPS:

More information

New Antihypertensive Strategies to Improve Blood Pressure Control

New Antihypertensive Strategies to Improve Blood Pressure Control New Antihypertensive Strategies to Improve Blood Pressure Control Antonio Coca, MD, PhD,, FRCP, FESC Hypertension and Vascular Risk Unit Department of Internal Medicine. Hospital Clínic (IDIBAPS) University

More information

Risk Assessment of developing type 2 diabetes mellitus in patient on antihypertensive medication

Risk Assessment of developing type 2 diabetes mellitus in patient on antihypertensive medication 41 Research Article Risk Assessment of developing type 2 diabetes mellitus in patient on antihypertensive medication Amarjeet Singh*, Sudeep bhardwaj, Ashutosh aggarwal Department of Pharmacology, Seth

More information

New Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets

New Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets New Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets Sidney C. Smith, Jr. MD, FACC, FAHA Professor of Medicine/Cardiology University of

More information

JNC 8 -Controversies. Sagren Naidoo Nephrologist CMJAH

JNC 8 -Controversies. Sagren Naidoo Nephrologist CMJAH JNC 8 -Controversies Sagren Naidoo Nephrologist CMJAH Joint National Committee (JNC) Panel appointed by the National Heart, Lung, and Blood Institute (NHLBI) First guidelines (JNC-1) published in 1977

More information

Hypertension. Risk of cardiovascular disease beginning at 115/75 mmhg doubles with every 20/10mm Hg increase. (Grade B)

Hypertension. Risk of cardiovascular disease beginning at 115/75 mmhg doubles with every 20/10mm Hg increase. (Grade B) Practice Guidelines and Principles: Guidelines and principles are intended to be flexible. They serve as reference points or recommendations, not rigid criteria. Guidelines and principles should be followed

More information

Management of High Blood Pressure in Adults

Management of High Blood Pressure in Adults Management of High Blood Pressure in Adults Based on the Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC8) James, P. A. (2014, February 05). 2014 Guideline for Management

More information

Difficult to Treat Hypertension

Difficult to Treat Hypertension Difficult to Treat Hypertension According to Goldilocks JNC 8 Blood Pressure Goals (2014) BP Goal 60 years old and greater*- systolic < 150 and diastolic < 90. (Grade A)** BP Goal 18-59 years old* diastolic

More information

Using the New Hypertension Guidelines

Using the New Hypertension Guidelines Using the New Hypertension Guidelines Kamal Henderson, MD Department of Cardiology, Preventive Medicine, University of North Carolina School of Medicine Kotchen TA. Historical trends and milestones in

More information

Jared Moore, MD, FACP

Jared Moore, MD, FACP Hypertension 101 Jared Moore, MD, FACP Assistant Program Director, Internal Medicine Residency Clinical Assistant Professor of Internal Medicine Division of General Medicine The Ohio State University Wexner

More information

major public health burden

major public health burden HYPERTENSION INTRODUCTION Hypertension is one of the major public health burden in the recent times. Hypertension remains a challenging medical condition among the noncommunicable diseases of ever growing

More information

Received: / Revised: / Accepted: / Published:

Received: / Revised: / Accepted: / Published: World Journal of Pharmaceutical Sciences ISSN (Print): 2321-3310; ISSN (Online): 2321-3086 Published by Atom and Cell Publishers All Rights Reserved Available online at: http://www.wjpsonline.org/ Original

More information

We are delighted to have Dr. Roetzheim with us today to discuss Managing Hypertension in Older Adult Patients.

We are delighted to have Dr. Roetzheim with us today to discuss Managing Hypertension in Older Adult Patients. Richard Roetzheim, MD, MSPH is Professor and Chair, Department of Family Medicine at the University of South Florida Morsani College of Medicine. Dr. Roetzheim has considerable experience leading NIH funded

More information

Evolving Concepts on Hypertension: Implications of Three Guidelines (JNC 8 Panel, ESH/ESC, NICE/BSH)

Evolving Concepts on Hypertension: Implications of Three Guidelines (JNC 8 Panel, ESH/ESC, NICE/BSH) Evolving Concepts on Hypertension: Implications of Three Guidelines (JNC 8 Panel, ESH/ESC, NICE/BSH) Sidney C. Smith, Jr. MD, FACC, FAHA, FESC Professor of Medicine/Cardiology University of North Carolina

More information

Hypertension Update Warwick Jaffe Interventional Cardiologist Ascot Hospital

Hypertension Update Warwick Jaffe Interventional Cardiologist Ascot Hospital Hypertension Update 2008 Warwick Jaffe Interventional Cardiologist Ascot Hospital Definition of Hypertension Continuous variable At some point the risk becomes high enough to justify treatment Treatment

More information

Hypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, Financial Disclosures

Hypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, Financial Disclosures Hypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, 2015 William C. Cushman, MD Professor, Preventive Medicine, Medicine, and Physiology University

More information

JMSCR Vol 06 Issue 05 Page May 2018

JMSCR Vol 06 Issue 05 Page May 2018 www.jmscr.igmpublication.org Impact Factor (SJIF): 6.379 Index Copernicus Value: 71.58 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v6i5.29 Trends in Prescribing Pattern

More information

Dr Narender Goel MD (Internal Medicine and Nephrology) Financial Disclosure: None, Conflict of Interest: None

Dr Narender Goel MD (Internal Medicine and Nephrology) Financial Disclosure: None, Conflict of Interest: None Dr Narender Goel MD (Internal Medicine and Nephrology) drnarendergoel@gmail.com Financial Disclosure: None, Conflict of Interest: None 12 th December 2013, New York Visit us at: http://kidneyscience.info/

More information

Volume 2 Number 2 (2011)

Volume 2 Number 2 (2011) Review of Global Medicine and Healthcare Research Volume 2 Number 2 (211) Publisher: DRUNPP Managed by: IOMC Group Website: www.iomcworld.com/rgmhr/ Drug Utilization Pattern and Co-morbidtities Among Hypertensive

More information

Incidental Findings; Management of patients presenting with high BP. Phil Swales

Incidental Findings; Management of patients presenting with high BP. Phil Swales Incidental Findings; Management of patients presenting with high BP Phil Swales Consultant Physician Acute & General Medicine University Hospitals of Leicester NHS Trust Objectives The approach to an incidental

More information

Don t let the pressure get to you:

Don t let the pressure get to you: Balanced information for better care Don t let the pressure get to you: Current evidence-based goals for treating hypertension A cornerstone of primary care: Lowering high blood pressure prevents cardiovascular

More information

Clinical guideline Published: 24 August 2011 nice.org.uk/guidance/cg127

Clinical guideline Published: 24 August 2011 nice.org.uk/guidance/cg127 Hypertension in adults: diagnosis and management Clinical guideline Published: 24 August 2011 nice.org.uk/guidance/cg127 NICE 2017. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).

More information

Hypertension Update Background

Hypertension Update Background Hypertension Update Background Overview Aaron J. Friedberg, MD Assistant Professor, Clinical Division of General Internal Medicine The Ohio State University Wexner Medical Center Management Guideline Comparison

More information

STUDY OF DRUG UITLIZATION PATTERN OF ANTIHYPERTENSIVE DRUGS IN HYPERTENSIVE NEPHROPATHY IN A TERTIARY CARE TEACHING HOSPITAL, BAREILLY, U.P.

STUDY OF DRUG UITLIZATION PATTERN OF ANTIHYPERTENSIVE DRUGS IN HYPERTENSIVE NEPHROPATHY IN A TERTIARY CARE TEACHING HOSPITAL, BAREILLY, U.P. RESEARCH ARTICLE STUDY OF DRUG UITLIZATION PATTERN OF ANTIHYPERTENSIVE DRUGS IN HYPERTENSIVE NEPHROPATHY IN A TERTIARY CARE TEACHING HOSPITAL, BAREILLY, U.P. Anju Madhwar 1,*, Dharmender Gupta 2, Sujata

More information

2/10/2014. Hypertension: Highlights of Hypertension Guidelines: Making the Most of Limited Evidence. Issues with contemporary guidelines

2/10/2014. Hypertension: Highlights of Hypertension Guidelines: Making the Most of Limited Evidence. Issues with contemporary guidelines Hypertension: 214 Highlights of Hypertension Guidelines: Making the Most of Limited Evidence Michael A, Weber, MD Editor-in-Chief, The Journal of Clinical Hypertension, Professor of Medicine, Division

More information

Hypertension Update. Objectives 4/28/2015. Beverly J. Mathis, D.O. OOA May 2015

Hypertension Update. Objectives 4/28/2015. Beverly J. Mathis, D.O. OOA May 2015 Hypertension Update Beverly J. Mathis, D.O. OOA May 2015 Objectives Learn new recommendations for BP treatment goals Approach to hypertension in the office Use of hypertensive drugs, and how to tailor

More information

RESISTENT HYPERTENSION. Dr. Helmy Bakr Professor and Head of Cardiology Dept. Mansoura University

RESISTENT HYPERTENSION. Dr. Helmy Bakr Professor and Head of Cardiology Dept. Mansoura University RESISTENT HYPERTENSION Dr. Helmy Bakr Professor and Head of Cardiology Dept. Mansoura University Resistant Hypertension Blood pressure remaining above goal in spite of concurrent use of 3 antihypertensive

More information

ADVANCES IN MANAGEMENT OF HYPERTENSION

ADVANCES IN MANAGEMENT OF HYPERTENSION Advances in Management of Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Current Status of Prevalence 29%; Blacks 33.5%

More information

Disclosures. Learning Objectives. Hypertension: a sprint to the finish Ontario Pharmacists Association 1

Disclosures. Learning Objectives. Hypertension: a sprint to the finish Ontario Pharmacists Association 1 Disclosures I have no current or past relationships with commercial entities I have received a speaker s fee from the Ontario Pharmacists Association for this learning activity Laura Tsang PharmD Sunnybrook

More information

Hypertension Update. Aaron J. Friedberg, MD

Hypertension Update. Aaron J. Friedberg, MD Hypertension Update Aaron J. Friedberg, MD Assistant Professor, Clinical Division of General Internal Medicine The Ohio State University Wexner Medical Center Background Diagnosis Management Overview Guideline

More information

Hypertension. Most important public health problem in developed countries

Hypertension. Most important public health problem in developed countries Hypertension Strategy for Continued Success in Treatment for the 21st Century November 15, 2005 Arnold B. Meshkov, M.D. Associate Professor of Medicine Temple University School of Medicine Philadelphia,

More information

C h a p t e r 1 7 JNC 7 Guidelines and Indian Scenario

C h a p t e r 1 7 JNC 7 Guidelines and Indian Scenario C h a p t e r 1 7 JNC 7 Guidelines and Indian Scenario M Paul Anand Consultant Physician, Lady Ratan Tata Medical Centre, M. Karve Road, Cooperage, Mumbai Executive Editor, API Textbook of Medicine Introduction

More information

Adherence to International Guidelines in the Management of Hypertension in a Tertiary Hospital in Nigeria

Adherence to International Guidelines in the Management of Hypertension in a Tertiary Hospital in Nigeria Tropical Journal of Pharmaceutical Research, June 2008; 7 (2): 945-952 Pharmacotherapy Group, Faculty of Pharmacy, University of Benin, Benin City, Nigeria. All rights reserved. Research Article Available

More information

Hypertension: JNC-7. Southern California University of Health Sciences Physician Assistant Program

Hypertension: JNC-7. Southern California University of Health Sciences Physician Assistant Program Hypertension: JNC-7 Southern California University of Health Sciences Physician Assistant Program Management and Treatment of Hypertension April 17, 2018, presented by Ezra Levy, Pharm.D.! Reference Card

More information

HYPERTENSION IN THE ELDERLY A BALANCED APPROACH. Barry Goldlist October 31, 2014

HYPERTENSION IN THE ELDERLY A BALANCED APPROACH. Barry Goldlist October 31, 2014 HYPERTENSION IN THE ELDERLY A BALANCED APPROACH Barry Goldlist October 31, 2014 DISCLOSURE I have not accepted any money for myself from any pharmaceutical company in the 21 st century I have accepted

More information

Reframe the Paradigm of Hypertension treatment Focus on Diabetes

Reframe the Paradigm of Hypertension treatment Focus on Diabetes Reframe the Paradigm of Hypertension treatment Focus on Diabetes Paola Atallah, MD Lecturer of Clinical Medicine SGUMC EDL monthly meeting October 25,2016 Overview Physiopathology of hypertension Classification

More information

Chapman University Digital Commons. Chapman University. Michael S. Kelly Chapman University,

Chapman University Digital Commons. Chapman University. Michael S. Kelly Chapman University, Chapman University Chapman University Digital Commons Pharmacy Faculty Articles and Research School of Pharmacy 12-30-2016 Assessment of Achieved Systolic Blood Pressure in Newly Treated Hypertensive Patients

More information

ADVANCES IN MANAGEMENT OF HYPERTENSION

ADVANCES IN MANAGEMENT OF HYPERTENSION Prevalence 29%; Blacks 33.5% About 72.5% treated; 53.5% uncontrolled (>140/90) Risk for poor control: Latinos, Blacks, age 18-44 and 80,

More information

OCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA

OCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA OMED 17 OCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA 29.5 Category 1-A CME credits anticipated ACOFP / AOA s 122 nd Annual Osteopathic Medical Conference & Exposition ACOFP - The Heart of the Matter - An Evidence

More information

Strategies for Managing Hypertension

Strategies for Managing Hypertension Strategies for Managing Hypertension by Marsha K. Millonig, MBA, RPh President,Catalyst Enterprises, LLC E.L.F. Publications, Inc. is accredited by the Accreditation Council for Pharmacy Education as a

More information

Pattern of Use of Anti-Hypertensive Drugs In a North Indian Tertiary Care Hospital Renu, Hema Chhabra, Anita Gupta, Neetu Sharma

Pattern of Use of Anti-Hypertensive Drugs In a North Indian Tertiary Care Hospital Renu, Hema Chhabra, Anita Gupta, Neetu Sharma Original Article Pattern of Use of Anti-Hypertensive Drugs In a North Indian Tertiary Care Hospital 1 1 2 3 Renu, Hema Chhabra, Anita Gupta, Neetu Sharma 1 2 3 Junior Resident, Professor and Head, Assistant

More information

Hypertension in 2015: SPRINT-ing ahead of JNC-8. MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic

Hypertension in 2015: SPRINT-ing ahead of JNC-8. MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic Hypertension in 2015: SPRINT-ing ahead of JNC-8 MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic Conflits of interest? None Disclaimer The opinions contained herein are not to be considered

More information

REDUCING COSTS AND IMPROVING HYPERTENSION MANAGEMENT

REDUCING COSTS AND IMPROVING HYPERTENSION MANAGEMENT REDUCING COSTS AND IMPROVING HYPERTENSION MANAGEMENT Vida Stankus 1, Brenda Hemmelgarn 2, Norm RC Campbell 2, Guanmin Chen 2, Finlay A McAlister 1, Ross T Tsuyuki 1 1 EPICORE Centre, Department of Medicine,

More information

Approximately 73.6 million adults in the United States have

Approximately 73.6 million adults in the United States have n clinical n Hypertension Treatment and Control Within an Independent Nurse Practitioner Setting Wendy L. Wright, MS; Joan E. Romboli, MSN; Margaret A. DiTulio, MS, MBA; Jenifer Wogen, MS; and Daniel A.

More information

Thiazide or Thiazide Like? Choosing Wisely Academic Detailing Conference Digby Pines October 12-14

Thiazide or Thiazide Like? Choosing Wisely Academic Detailing Conference Digby Pines October 12-14 Thiazide or Thiazide Like? Choosing Wisely Academic Detailing Conference Digby Pines October 12-14 Disclosures Pam McLean-Veysey, Team Leader Drug Evaluation Unit DEU funded by the Drug Evaluation Alliance

More information

Causes of Poor BP control Rates

Causes of Poor BP control Rates Goals Of Hypertension Management in Clinical Practice World Hypertension League (WHL) Meeting Adel E. Berbari, MD, FAHA, FACP Professor of Medicine and Physiology Head, Division of Hypertension and Vascular

More information

Reducing proteinuria

Reducing proteinuria Date written: May 2005 Final submission: October 2005 Author: Adrian Gillin Reducing proteinuria GUIDELINES a. The beneficial effect of treatment regimens that include angiotensinconverting enzyme inhibitors

More information

None. Disclosure: Relationships with Industry Conflicts of Interests. Learning Objectives: Participants will be able to:

None. Disclosure: Relationships with Industry Conflicts of Interests. Learning Objectives: Participants will be able to: 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC 8) James W. Shaw, MD Memorial Lecture

More information

Hypertension Update 2009

Hypertension Update 2009 Hypertension Update 2009 New Drugs, New Goals, New Approaches, New Lessons from Clinical Trials Timothy C Fagan, MD, FACP Professor Emeritus University of Arizona New Drugs Direct Renin Inhibitors Endothelin

More information

Primary hypertension in adults

Primary hypertension in adults Primary hypertension in adults NICE provided the content for this booklet which is independent of any company or product advertised Hypertension Welcome NICE published an updated guideline on the diagnosis

More information

2017 High Blood Pressure Clinical Practice Guideline

2017 High Blood Pressure Clinical Practice Guideline 2017 High Blood Pressure Clinical Practice Guideline Applying the Latest Hypertension Guideline to Your Practice Carmine D Amico, D.O., F.A.C.C. 2017 ACC / AHA / AAPA / ABC / ACPM / AGS / APhA / ASH /

More information

Hypertension diagnosis (see detail document) Diabetic. Target less than 130/80mmHg

Hypertension diagnosis (see detail document) Diabetic. Target less than 130/80mmHg Hypertension diagnosis (see detail document) Non-diabetic Diabetic Very elderly (older than 80 years) Target less than 140/90mmHg Target less than 130/80mmHg Consider SBP target less than 150mmHg Non-diabetic

More information

Hypertension Putting the Guidelines into Practice

Hypertension Putting the Guidelines into Practice Hypertension 2017 Putting the Guidelines into Practice Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or

More information

Antihypertensive Trial Design ALLHAT

Antihypertensive Trial Design ALLHAT 1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes

More information

Outcomes and Perspectives of Single-Pill Combination Therapy for the modern management of hypertension

Outcomes and Perspectives of Single-Pill Combination Therapy for the modern management of hypertension Outcomes and Perspectives of Single-Pill Combination Therapy for the modern management of hypertension Prof. Massimo Volpe, MD, FAHA, FESC, Chair of Cardiology, Department of Clinical and Molecular Medicine

More information

Variability in Blood Pressure Medications Prescribed to Stroke Patients at Hospital Discharge

Variability in Blood Pressure Medications Prescribed to Stroke Patients at Hospital Discharge Variability in Blood Pressure Medications Prescribed to Stroke Patients at Hospital Discharge A. Lantzy, MSN, RN, L. Simo, A. Carlson-Chalifoux, MS, RN, AGACNP-BC, CCRN, SCRN, P. Feit, MS, A. Sharrief,

More information

Summary of recommendations

Summary of recommendations Summary of recommendations Measuring blood pressure (BP) Use the recommended technique at every BP reading to ensure accurate measurements and avoid common errs. Pay particular attention to the following:

More information

2003 World Health Organization (WHO) / International Society of Hypertension (ISH) Statement on Management of Hypertension.

2003 World Health Organization (WHO) / International Society of Hypertension (ISH) Statement on Management of Hypertension. 2003 World Health Organization (WHO) / International Society of Hypertension (ISH) Statement on Management of Hypertension Writing Group: Background Hypertension worldwide causes 7.1 million premature

More information